Efficacy and Safety of Radioactive 125 I Seed Implantation for Patients with Oligo-Recurrence Soft Tissue Sarcomas

Purpose To evaluate the efficacy and safety of computed tomography-guided radioactive iodine-125 ( 125 I) seed implantation for oligo-recurrence soft tissue sarcomas following surgical resection. Materials and Methods Patients with oligo-recurrence soft tissue sarcomas after curative surgical resection between June 2013 and December 2020 were included. The primary outcome measure was objective response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The secondary outcomes included progression-free survival, overall survival, and safety profiles. Results Twenty-nine patients receiving computed tomography-guided 125 I seed implantation were included in the study. The objective response rates at 2-, 6- and 12-month follow-up were 48.3%, 65.5% and 40.9%, respectively. The median progression-free survival was 11.3 months. The median overall survival was 25.1 months, with a 1- and 2-year overall survival rate of 81.5% and 50.0%, respectively. No severe treatment-related adverse effects occured. Conclusion 125 I seed implantation has the potential to be an effective and safe treatment for oligo-recurrence soft tissue sarcomas after surgical resection.